Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
~Pharmacokinetic data from patients treated in the study show that infusion of pegunigalsidase alfa every 4 weeks results in the presence of continuous active enzyme throughout the entire infusion...
-
~Oral presentation to include pharmacokinetic and anti-drug antibody data for first 15 patients enrolled~ CARMIEL, Israel, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,...
-
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
-
CARMIEL, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
-
CARMIEL, Israel, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
-
~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A deterioration trend in patients’...
-
Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102) A deterioration trend in patients’ kidney...
-
CARMIEL, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization...
-
Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
CARMIEL, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and...
-
CARMIEL, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), announced today that the Company’s Board of Directors has appointed Mr. David...